Vogenx, Inc.

Nasdaq: VOGX

Day 59 public/EARLY PUBLIC/IPO Aug 12, 2026/Pharmaceutical Preparations

$17.56

▲ 0.07 (+0.40%)

LIVE

updated 15h ago

Intelligence Core

OBSERVING

New SEC filing in the last 72 h

Current missionThesis Test · Day 31–90

Test the initial thesis against the first earnings, guidance and execution.

Focus

EarningsGuidanceExecutionInstitutional changes

CAUTIOUSFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence65%

CURRENT THESIS INTERPRETED

Vogenx, Inc. is an early public clinical-stage pharmaceutical company trading at $17.56 with active insider and institutional filing activity. Fundamentals show a net loss and cash burn typical of the sector, resulting in high risk assigned to its newly public status.

Momentum

Price · since IPOLIVE

Yahoo · 42 pts

H $34.13L $13.00Last $17.56

Current ThesisINTERPRETEDLIVE

Why

+High narrative activity with 4 Form 8-K filings and 16 insider forms recorded with the SEC
+Institutional presence noted via 1 Schedule 13D/13G disclosure
+Stable near-term price momentum with a minor 1-day move of plus 0.40 percent

Risks

−Newly public status under 90 days with a risk score of 78
−Clinical-stage pharmaceutical sector exposure
−Fundamentals reflect ongoing net losses and reliance on balance sheet cash

Catalysts

→Future clinical pipeline updates via SEC filings
→Additional institutional ownership disclosures

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://vogenx.com

VIEW-ONLY

Visit

LIVE · SANDBOXED · source: SEC 424B4

Resolving official website…

Research EnvironmentLIVE

Research environment · $VOGXSEC · market · news

22 evidence items|newest evidence 23h ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 58/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore OBSERVING · New SEC filing in the last 72 h. Mission: Thesis Test.via Intelligence Core

15h agoOBSERVATIONVERIFIEDLast price $17.56 · +0.40% on the day.via Finnhub quoteVERIFIED

23h agoEVIDENCEVogenx Appoints Board Member Richard Gorman as Chief Commercial Officervia Yahoo · tier 3, cross-check Oct 9, 2026EVIDENCEVERIFIEDForm 8-K filed · FORM 8-K.via SEC EDGARVERIFIED Oct 6, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED Oct 6, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED Oct 6, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED Oct 6, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED 15d agoEVIDENCE12 Health Care Stocks Moving In Thursday's After-Market Sessionvia Benzinga · tier 3, cross-check 17d agoEVIDENCE12 Health Care Stocks Moving In Tuesday's Intraday Sessionvia Benzinga · tier 3, cross-check

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-10-09	8-K	FORM 8-K	SEC ↗
2026-10-06	4	Vogenx, Inc.	SEC ↗
2026-10-06	4	Vogenx, Inc.	SEC ↗
2026-10-06	4	Vogenx, Inc.	SEC ↗
2026-10-06	4	Vogenx, Inc.	SEC ↗

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics